Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9709
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Erkurt, M.A. | - |
dc.contributor.author | Berber, I. | - |
dc.contributor.author | Tekgündüz, E. | - |
dc.contributor.author | Doğu, Mehmet Hilmi | - |
dc.contributor.author | Korkmaz, S. | - |
dc.contributor.author | Demir, C. | - |
dc.contributor.author | Yilmaz, M. | - |
dc.date.accessioned | 2019-08-16T13:04:53Z | |
dc.date.available | 2019-08-16T13:04:53Z | |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1473-0502 | - |
dc.identifier.uri | https://hdl.handle.net/11499/9709 | - |
dc.identifier.uri | https://doi.org/10.1016/j.transci.2016.01.018 | - |
dc.description.abstract | We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. © 2016 Elsevier Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Ltd | en_US |
dc.relation.ispartof | Transfusion and Apheresis Science | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Autologous stem cell transplantation | en_US |
dc.subject | CNS lymphoma | en_US |
dc.subject | High-dose chemotherapy | en_US |
dc.subject | Methotrexate | en_US |
dc.subject | PCNSL | en_US |
dc.subject | busulfan | en_US |
dc.subject | cyclophosphamide | en_US |
dc.subject | cytarabine | en_US |
dc.subject | etoposide | en_US |
dc.subject | melphalan | en_US |
dc.subject | thiotepa | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | Article | en_US |
dc.subject | autologous stem cell transplantation | en_US |
dc.subject | cancer chemotherapy | en_US |
dc.subject | cancer prognosis | en_US |
dc.subject | cancer radiotherapy | en_US |
dc.subject | female | en_US |
dc.subject | follow up | en_US |
dc.subject | general practice | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | medical record review | en_US |
dc.subject | mortality | en_US |
dc.subject | multicenter study | en_US |
dc.subject | overall survival | en_US |
dc.subject | primary central nervous system lymphoma | en_US |
dc.subject | recurrence free survival | en_US |
dc.subject | relapse | en_US |
dc.subject | remission | en_US |
dc.subject | retrospective study | en_US |
dc.subject | very elderly | en_US |
dc.subject | autotransplantation | en_US |
dc.subject | Central Nervous System Neoplasms | en_US |
dc.subject | clinical practice | en_US |
dc.subject | clinical trial | en_US |
dc.subject | demography | en_US |
dc.subject | lymphoma | en_US |
dc.subject | middle aged | en_US |
dc.subject | recurrent disease | en_US |
dc.subject | stem cell transplantation | en_US |
dc.subject | young adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Aged, 80 and over | en_US |
dc.subject | Demography | en_US |
dc.subject | Humans | en_US |
dc.subject | Lymphoma | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Practice Patterns, Physicians' | en_US |
dc.subject | Recurrence | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Stem Cell Transplantation | en_US |
dc.subject | Transplantation, Autologous | en_US |
dc.subject | Young Adult | en_US |
dc.title | Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 54 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 80 | |
dc.identifier.startpage | 80 | en_US |
dc.identifier.endpage | 84 | en_US |
dc.identifier.doi | 10.1016/j.transci.2016.01.018 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 26810141 | en_US |
dc.identifier.scopus | 2-s2.0-84956890309 | en_US |
dc.identifier.wos | WOS:000374614700015 | en_US |
dc.identifier.scopusquality | Q3 | - |
dc.owner | Pamukkale University | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
3
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
2
checked on Nov 14, 2024
Page view(s)
54
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.